Cases & Deals

Sanofi sells two established product portfolios to Neuraxpharm

Clients Sanofi

Jones Day advised Sanofi in the sale of 2 portfolios of products for central nervous systems disorders and pain and vascular diseases to LESVI, a Spanish subsidiary of Neuraxpharm. These portfolios include 17 molecules representing 38 brands marketed in over 50 countries, including Dogmatil, Tranxene and Trental.